TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38085798

Group type: EXPERIMENTAL
Intervention: Intracorporeal anastomosis (IA)
Number of subjects: 342

Group type: COMPARATOR
Intervention: Extracorporeal anastomosis (EA)
Number of subjects: 342
Study: 38085846

Group type: EXPERIMENTAL
Intervention: Riliprubart 30 mg/kg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Riliprubart 15 mg/kg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Riliprubart (both doses)
Number of subjects: 12
Study: 38086156

Group type: EXPERIMENTAL
Intervention: Resamirigene bilparvovec (AT132)
Number of subjects: 10
Study: 38086377

Group type: EXPERIMENTAL
Intervention: Protein/phosphoprotein-based signatures
Number of subjects: 736

Group type: EXPERIMENTAL
Intervention: Dichotomous HER2 activation response predictive signature
Number of subjects: 736
Study: 38086444

Group type: EXPERIMENTAL
Intervention: Pain Coping Skills Training (PCST)
Number of subjects: 640

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: Buprenorphine (offered to participants taking prescription opioid medications at an average dose of ≥20 morphine milligram equivalents per day)
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: PCST and Usual Care (at 24 weeks)
Number of subjects: 640
Study: 38086524

Group type: EXPERIMENTAL
Intervention: Recombinant human parathyroid hormone (1-84) (rhPTH[1-84])
Number of subjects: 39
Study: 38086585

Group type: EXPERIMENTAL
Intervention: Safety Planning Intervention with structured follow-up (SPI+)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Collaborative Assessment and Management of Suicidality (CAMS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 0
Study: 38086587

Group type: EXPERIMENTAL
Intervention: Medical hypnosis (MH) and cardiac coherence (CC) training, starting 7 days before surgery.
Number of subjects: 296

Group type: COMPARATOR
Intervention: Standard treatment to manage preoperative anxiety (Control).
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Medical hypnosis (MH) and cardiac coherence (CC) training.
Number of subjects: 296
Study: 38086588

Group type: EXPERIMENTAL
Intervention: Intelligent Hypertension Management System (IHMS) management group (n=160)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Conventional care group (n=160)
Number of subjects: 320
Study: 38086595

Group type: EXPERIMENTAL
Intervention: Methylphenidate (long-release capsule, doses 18-36-54 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lisdexamphetamine (LDX, 30-50-70 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 38086910

Group type: EXPERIMENTAL
Intervention: MINOCA patients with an initial normal CMR scan
Number of subjects: 15

Group type: COMPARATOR
Intervention: Age- and sex-matched volunteers
Number of subjects: 15
Study: 38086998

Group type: EXPERIMENTAL
Intervention: Imaradenant 50 mg QD
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Imaradenant 75 mg QD
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Imaradenant (50 mg and 75 mg QD)
Number of subjects: 10
Study: 38087071

Group type: EXPERIMENTAL
Intervention: Hypothyroidism
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: Elevated TSH levels
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: Lower T3 levels
Number of subjects: 496
Study: 38087139

Group type: EXPERIMENTAL
Intervention: Complete Mesocolic Excision (CME)
Number of subjects: 258

Group type: COMPARATOR
Intervention: Conventional Surgery
Number of subjects: 258
Study: 38087258

Group type: EXPERIMENTAL
Intervention: Salivary LINC00657
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Salivary miR-106a
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Salivary LINC00657 and miR-106a
Number of subjects: 36
Study: 38087306

Group type: EXPERIMENTAL
Intervention: RealConsent2.0/alcohol
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: RealConsent2.0/placebo
Number of subjects: 605

Group type: COMPARATOR
Intervention: RealConsent1.0/alcohol
Number of subjects: 605

Group type: COMPARATOR
Intervention: RealConsent1.0/placebo
Number of subjects: 605

Group type: COMPARATOR
Intervention: Taking Charge/alcohol
Number of subjects: 605

Group type: COMPARATOR
Intervention: Taking Charge/placebo
Number of subjects: 605
Study: 38087329

Group type: EXPERIMENTAL
Intervention: 3% diquafosol (DQS) eye drops, one drop, six times per day for 8 weeks
Number of subjects: 202

Group type: COMPARATOR
Intervention: 0.1% hyaluronic acid (HA) eye drops, one drop, six times per day for 8 weeks
Number of subjects: 202
Study: 38087393

Group type: EXPERIMENTAL
Intervention: Clinical coach employed a standard template to structure coach calls with the NH champion
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dissemination of materials to family and providers and distribution of tools to staff
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Implementation of structured behavioral intervention to improve UTI recognition and management
Number of subjects: 30
Study: 38087394

Group type: EXPERIMENTAL
Intervention: UCB + EPO
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: UCB
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: EPO
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 38087800

Group type: EXPERIMENTAL
Intervention: Cemented femoral stem (Lubinus SP II)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Uncemented femoral stem
Number of subjects: 61
Study: 38087949

Group type: EXPERIMENTAL
Intervention: Prediction model using clinical features (cognitive function assessments, APOE ε4 status, demographics, and brain MRI measures)
Number of subjects: 934
Study: 38087967

Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa (BA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pembrolizumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa (BA) in NSCLC
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pembrolizumab in NSCLC
Number of subjects: 0
Study: 38088154

Group type: EXPERIMENTAL
Intervention: Daily physical activity measured by wearable smartwatch (Huawei smartwatch)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Baseline step counts within 1 month since discharge
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Daily step counts
Number of subjects: 222
Study: 38088156

Group type: EXPERIMENTAL
Intervention: Standard immunosuppression treatment with eltrombopag (Group B)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard immunosuppression treatment (Group A)
Number of subjects: 0
Study: 38088422

Group type: EXPERIMENTAL
Intervention: Time-updated ambulatory blood pressure (BP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Office systolic blood pressure (SBP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Day-time ambulatory SBP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Night-time ambulatory SBP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mean ambulatory SBP
Number of subjects: 0
Study: 38088425

Group type: EXPERIMENTAL
Intervention: Testosterone Replacement Therapy (TRT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 38088463

Group type: EXPERIMENTAL
Intervention: hs-cTnT ESC 0/1-h algorithm in the rule-out zone
Number of subjects: 1422
Study: 38088558

Group type: EXPERIMENTAL
Intervention: Ziltivekimab 7.5 mg
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Ziltivekimab 15 mg
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Ziltivekimab 30 mg
Number of subjects: 264

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Ziltivekimab (all doses)
Number of subjects: 264
Study: 38088562

Group type: EXPERIMENTAL
Intervention: B.1.640.1 variant
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: B.1.640.1 Spike
Number of subjects: 1100
Study: 38088668

Group type: EXPERIMENTAL
Intervention: Telehealth Serious Illness Care Program (SICP)
Number of subjects: 20
Study: 38088765

Group type: EXPERIMENTAL
Intervention: ECPR patients with favorable neurologic outcome
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: ECPR patients with ET co2 less than 10 mm Hg
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: High-quality CPR
Number of subjects: 97
Study: 38088821

Group type: EXPERIMENTAL
Intervention: Oral steroids (prednisolone for 7 to 14 days)
Number of subjects: 2770

Group type: COMPARATOR
Intervention: Topical (intranasal) steroids (various preparations for 2 weeks to 3 months)
Number of subjects: 2770
Study: 38088947

Group type: EXPERIMENTAL
Intervention: Lower uric acid (UA) in middle age group
Number of subjects: 36550

Group type: EXPERIMENTAL
Intervention: Higher uric acid (UA) in middle age group
Number of subjects: 36550

Group type: EXPERIMENTAL
Intervention: Lower uric acid (UA) in elder age group
Number of subjects: 36550

Group type: EXPERIMENTAL
Intervention: Higher uric acid (UA) in elder age group
Number of subjects: 36550
Study: 38088983

Group type: EXPERIMENTAL
Intervention: RSV-LRTI
Number of subjects: 2094

Group type: EXPERIMENTAL
Intervention: Severe RSV-LRTI
Number of subjects: 2094

Group type: EXPERIMENTAL
Intervention: All-cause LRTI
Number of subjects: 2094
Study: 38089057

Group type: EXPERIMENTAL
Intervention: Peroral administration of a capsule containing purified DMT and harmine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Combined administration of an oromucosal harmine tablet and an intranasal DMT spray
Number of subjects: 10
Study: 38089061

Group type: EXPERIMENTAL
Intervention: Combined supplement of standardized dry extracts of amla
Number of subjects: 0
Study: 38089167

Group type: EXPERIMENTAL
Intervention: Standard of care treatment
Number of subjects: 312
Study: 38089679

Group type: EXPERIMENTAL
Intervention: Pre-existing injury complaints (ICPR)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Higher fitness subjective state
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Illness during the season
Number of subjects: 320
Study: 38089924

Group type: EXPERIMENTAL
Intervention: 16 g broccoli sprouts
Number of subjects: 12

Group type: COMPARATOR
Intervention: Pea sprouts (placebo)
Number of subjects: 12
Study: 38090266

Group type: EXPERIMENTAL
Intervention: Subcutaneous interferon beta-1a (sc IFN β-1a) treatment
Number of subjects: 577

Group type: EXPERIMENTAL
Intervention: Patient support programme (PSP)
Number of subjects: 577
Study: 38090597

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 BNT162b2 mRNA vaccination
Number of subjects: 0
Study: 38090743

Group type: EXPERIMENTAL
Intervention: BFR at 80% arterial occlusion pressure (AOP)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: BFR at 40% arterial occlusion pressure (AOP)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (no BFR)
Number of subjects: 17
Study: 38090880

Group type: EXPERIMENTAL
Intervention: HMP-O2
Number of subjects: 179

Group type: COMPARATOR
Intervention: SCS
Number of subjects: 179
Study: 38090987

Group type: EXPERIMENTAL
Intervention: Eplerenone, 50 mg, twice a day
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 38091109

Group type: EXPERIMENTAL
Intervention: ERAS
Number of subjects: 456

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 456
Study: 38091212

Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 32
Study: 38091246

Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 90
Study: 38091416

Group type: EXPERIMENTAL
Intervention: Near-infrared group (indocyanine green)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Non-near-infrared group
Number of subjects: 108
Study: 38091501

Group type: EXPERIMENTAL
Intervention: ANB at the onset
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study: 38091531

Group type: EXPERIMENTAL
Intervention: High-dose recombinant influenza vaccine (Flublok Quadrivalent)
Number of subjects: 1630328

Group type: COMPARATOR
Intervention: Standard-dose influenza vaccines
Number of subjects: 1630328
Study: 38091530

Group type: EXPERIMENTAL
Intervention: mRNA-1345 (50 μg)
Number of subjects: 35541

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35541
Study: 38091578

Group type: EXPERIMENTAL
Intervention: T-reg graft alone
Number of subjects: 24

Group type: COMPARATOR
Intervention: T-reg graft plus tacrolimus
Number of subjects: 24
Study: 38091943

Group type: EXPERIMENTAL
Intervention: Transanal total mesorectal resection (taTME)
Number of subjects: 2502

Group type: COMPARATOR
Intervention: Laparoscopic total mesorectal excision (laTME)
Number of subjects: 2502
Study: 38092009

Group type: EXPERIMENTAL
Intervention: Golidocitinib 150 mg once daily until disease progression or other discontinuation criteria were met.
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Golidocitinib 150 mg once daily
Number of subjects: 88
Study: 38092151

Group type: EXPERIMENTAL
Intervention: Folic Acid (FA) supplementation at 800 μg/day for 12 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 38092153

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (5 mg oral daily)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 50
Study: 38092225

Group type: EXPERIMENTAL
Intervention: Dupilumab 100/200 mg by bodyweight every 2 weeks for 52 weeks
Number of subjects: 175

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 175
Study: 38092228

Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan (SG) for four cycles
Number of subjects: 50
Study: 38092272

Group type: EXPERIMENTAL
Intervention: Beetroot juice nitrate-rich (BRJ-NO3), 800 mg of NO
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 38092285

Group type: EXPERIMENTAL
Intervention: Shared decision making
Number of subjects: 0

Group type: COMPARATOR
Intervention: Motivational interviewing plus cognitive behavioral therapy
Number of subjects: 0
Study: 38092790

Group type: EXPERIMENTAL
Intervention: Mazdutide (up to 6 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38092805

Group type: EXPERIMENTAL
Intervention: Coherent breathing at ~5.5 breaths/min for ~10 min/day over 4 weeks
Number of subjects: 400

Group type: COMPARATOR
Intervention: Matched attention-placebo at 12 breaths/min for ~10 min/day over 4 weeks
Number of subjects: 400
Study: 38092871

Group type: EXPERIMENTAL
Intervention: Serum choline levels (highest levels Q4)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Elevated choline levels (per SD, 11.49 μg/mL)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Lowest choline levels (Q1 group)
Number of subjects: 199
Study: 38092897

Group type: EXPERIMENTAL
Intervention: AP30663, an inhibitor of the K channel
Number of subjects: 0
Study: 38093118

Group type: EXPERIMENTAL
Intervention: Preoperative cardiopulmonary exercise test (CPET) variables, specifically the slope of the relation between minute ventilation and carbon dioxide production (VE/VCO2)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Multivariate analysis adjusted for surgical approach (open vs minimally invasive)
Number of subjects: 102
Study: 38093181

Group type: EXPERIMENTAL
Intervention: Low eosinophil count <0.01 G/L
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Eosinophil count 0-0.07 G/L
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Eosinophil count 0.07-0.172 G/L
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Eosinophil count <0.01 G/L
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: CIBLE score
Number of subjects: 156
Study: 38093374

Group type: EXPERIMENTAL
Intervention: Body-weight support (BWS) gait training
Number of subjects: 33
Study: 38093381

Group type: EXPERIMENTAL
Intervention: Dry suction technique
Number of subjects: 200

Group type: COMPARATOR
Intervention: Wet suction technique
Number of subjects: 200
Study: 38093394

Group type: EXPERIMENTAL
Intervention: Functional training with elastic band
Number of subjects: 41

Group type: COMPARATOR
Intervention: Resistance exercise (machine resistance)
Number of subjects: 41
Study: 38093439

Group type: EXPERIMENTAL
Intervention: Liberal transfusion strategy (Hgb threshold 7.0 g/dL)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Conservative transfusion strategy (Hgb threshold 5.5 g/dL)
Number of subjects: 65
Study: 38093467

Group type: EXPERIMENTAL
Intervention: High Empowerment
Number of subjects: 633

Group type: EXPERIMENTAL
Intervention: Moderately High Empowerment
Number of subjects: 633

Group type: EXPERIMENTAL
Intervention: Normative
Number of subjects: 633

Group type: EXPERIMENTAL
Intervention: Low Empowerment
Number of subjects: 633

Group type: EXPERIMENTAL
Intervention: High Information
Number of subjects: 633
Study: 38093803

Group type: EXPERIMENTAL
Intervention: internet-delivered cognitive behavioural therapy (iCBT) program for 9 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Online Depression Feedback (ODF) group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both iCBT and ODF
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: iCBT
Number of subjects: 0
Study: 38093975

Group type: EXPERIMENTAL
Intervention: Rutan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 38094620

Group type: EXPERIMENTAL
Intervention: FFT-MCC (Family-focused therapy with MyCoachConnect app)
Number of subjects: 65

Group type: COMPARATOR
Intervention: FFT-Track (Family-focused therapy with mood tracking only)
Number of subjects: 65
Study: 38094629

Group type: EXPERIMENTAL
Intervention: Tumor Treating Fields (TTFields) therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tumor Treating Fields (TTFields)
Number of subjects: 0
Study: 38094931

Group type: EXPERIMENTAL
Intervention: Lessons in Affect Regulation to Keep Stress and Pain UndeR control (LARKSPUR)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 95
Study: 38094933

Group type: EXPERIMENTAL
Intervention: Pain Identification and Communication Toolkit (PICT)
Number of subjects: 100
Study: 38095056

Group type: EXPERIMENTAL
Intervention: HER3-DXd (patritumab deruxtecan)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Platinum-based chemotherapy
Number of subjects: 0
Study: 38095330

Group type: EXPERIMENTAL
Intervention: Post-stroke aphasia
Number of subjects: 23
Study: 38095452

Group type: EXPERIMENTAL
Intervention: Pittsburgh Sleep Quality Index (PSQI)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: PSQI and ASPI
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: PSQI and BASFI
Number of subjects: 99
Study: 38095657

Group type: EXPERIMENTAL
Intervention: Survodutide (dose-response effects)
Number of subjects: 413

Group type: COMPARATOR
Intervention: Semaglutide
Number of subjects: 413

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 413
Study: 38095673

Group type: EXPERIMENTAL
Intervention: Photon RT
Number of subjects: 35

Group type: COMPARATOR
Intervention: Proton RT
Number of subjects: 35
Study: 38095675

Group type: EXPERIMENTAL
Intervention: Abatacept (ABA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38095692

Group type: EXPERIMENTAL
Intervention: Ustekinumab (90 mg every 8 or 12 weeks)
Number of subjects: 348
Study: 38095714

Group type: EXPERIMENTAL
Intervention: Lung ultrasound-guided fluid resuscitation (LUGFR)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Usual fluid resuscitation (Control)
Number of subjects: 72
Study: 38095713

Group type: EXPERIMENTAL
Intervention: Munich Berlin Symptom Questionnaires (MBSQs) and supplementary scoring sheets (SSSs)
Number of subjects: 10
Study: 38095797

Group type: EXPERIMENTAL
Intervention: Multidimensional intervention (patient education, physical exercise, CBT-based group program, nutritional counselling)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Multidimensional intervention
Number of subjects: 7
Study: 38095800

Group type: COMPARATOR
Intervention: Standard of Care
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: oXiris
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Toraymyxin
Number of subjects: 30
Study: 38095878

Group type: EXPERIMENTAL
Intervention: Carboplatin and atezolizumab (1200 mg every 3 weeks)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Carboplatin alone
Number of subjects: 106
Study: 38095881

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy with bevacizumab
Number of subjects: 617

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy without bevacizumab
Number of subjects: 617

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy with carboplatin
Number of subjects: 617

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy with cisplatin
Number of subjects: 617

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy with prior CRT
Number of subjects: 617

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy without prior CRT
Number of subjects: 617

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy in squamous type
Number of subjects: 617

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy in nonsquamous type
Number of subjects: 617

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy with bevacizumab (intention-to-treat)
Number of subjects: 617

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy without bevacizumab (intention-to-treat)
Number of subjects: 617

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy with carboplatin (intention-to-treat)
Number of subjects: 617

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy with cisplatin (intention-to-treat)
Number of subjects: 617

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy with prior CRT (intention-to-treat)
Number of subjects: 617

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy without prior CRT (intention-to-treat)
Number of subjects: 617

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy in squamous type (intention-to-treat)
Number of subjects: 617

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy in nonsquamous type (intention-to-treat)
Number of subjects: 617
Study: 38095903

Group type: EXPERIMENTAL
Intervention: Primary snoring (AHI <1)
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: Mild obstructive sleep apnea (AHI 1-3)
Number of subjects: 459

Group type: COMPARATOR
Intervention: Demographic and clinical characteristics
Number of subjects: 459

Group type: COMPARATOR
Intervention: Weighted combination of clinical predictors
Number of subjects: 459
Study: 38095899

Group type: EXPERIMENTAL
Intervention: Evidence-based checklist administered every 6 hours from enrollment to organ retrieval.
Number of subjects: 1535

Group type: EXPERIMENTAL
Intervention: Adherence to the checklist higher than 79.0%.
Number of subjects: 1535

Group type: COMPARATOR
Intervention: Usual care provided to control group.
Number of subjects: 1535